Alnylam Chief Commercial Officer Tolga Tanguler Departs
Alnylam Pharmaceuticals announced its Chief Commercial Officer is leaving as the company authorizes a $1 billion share repurchase program.
Updated on Nov. 5, 2026 in Biotech
Alnylam Pharmaceuticals announced that Chief Commercial Officer Tolga Tanguler is leaving the company, with no reason given for the departure. The announcement came alongside a $1 billion share repurchase authorization.
Why it matters
The departure comes after Alnylam's stock fell 20% following its quarterly earnings release, after the company cut full-year guidance when Amvuttra sales disappointed. The company is working with an executive search firm to select its next Chief Commercialization Officer.
Amvuttra, approved in 2022 for polyneuropathy of hereditary transthyretin-mediated amyloidosis and expanded in 2025 to certain patients with cardiomyopathy, generated $1.13 billion in third-quarter sales. The release did not explain the reason for the departure.
The players
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a Cambridge, Massachusetts-based biotechnology company focused on RNA interference therapeutics, including its Amvuttra treatment for transthyretin-mediated amyloidosis.
Tolga Tanguler
Tolga Tanguler served as Chief Commercial Officer of Alnylam Pharmaceuticals, overseeing the commercial launch and sales of the company's medicines.
The details
Tanguler's departure was announced in a company release, and the change appears to be immediate. Alnylam cut its full-year guidance after Amvuttra sales disappointed, and analyst William Blair said it is difficult to assess near-term 2027 revenue estimates.
Timeline
July 2026: Alnylam's stock fell as much as 29% after second-quarter earnings and a lowered forecast.
October 29, 2026: Third-quarter earnings showed Amvuttra sales in line with expectations, but the stock fell 20%.
November 5, 2026: Tanguler's departure and the $1 billion buyback were announced.
Roadmap
The commercial leadership change follows disappointing sales of Amvuttra, first approved in 2022 and expanded in 2025 to include certain cardiomyopathy patients. Amvuttra's $1.13 billion in third-quarter sales sits at the center of Alnylam's current commercial strategy.
For patients and clinicians, the leadership change does not alter Amvuttra's approved indications or availability. The 20% stock decline and $1 billion buyback mainly affect shareholders and the company's near-term commercial planning.
The takeaway
Leadership transitions at commercial-stage biotechs often follow sales shortfalls, and the search for a successor will show how Alnylam plans to rebuild momentum for its flagship drug. Investors and observers should watch the next update on the Chief Commercialization Officer selection.
What happens next
Alnylam anticipates providing an update on its Chief Commercialization Officer selection in due course.
Further reading
For more on the sector, see Biotech coverage of drug developers and their commercial strategies.
Source note: This article includes information reported by FiercePharma.
